GlyCardial Diagnostics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 6

GlyCardial Diagnostics General Information

Description

Developer of novel biomarkers intended to improve the early diagnosis of cardiac ischemic events to reduce the impact of the disease on patients' life. The company's biomarkers prevent irreversible myocardial damage and heart failure by helping in the early diagnosis of ischemia, enabling patients to avoid evolution after an ischemic event.

Contact Information

Website
www.glycardial.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Parc Científic De Barcelona
  • Tower I, Floor 5, A08, Baldiri Reixac 4-8
  • 08028 Barcelona
  • Spain
+34 934
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Parc Científic De Barcelona
  • Tower I, Floor 5, A08, Baldiri Reixac 4-8
  • 08028 Barcelona
  • Spain
+34 934

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GlyCardial Diagnostics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 01-Apr-2025 Completed Clinical Trials - General
5. Early Stage VC 30-Mar-2021 Completed Clinical Trials - General
4. Grant 27-Jan-2021 Completed Clinical Trials - General
3. Early Stage VC 10-Dec-2018 Completed Clinical Trials - General
2. Grant 05-Dec-2018 $2.22M $1.99M Completed Clinical Trials - General
1. Seed Round 10-Nov-2017 $1.99M $1.99M Completed Startup
To view GlyCardial Diagnostics’s complete valuation and funding history, request access »

GlyCardial Diagnostics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary 2,030 $1.191768 $587.1 $587.1 1x $587.1 25.93%
To view GlyCardial Diagnostics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

GlyCardial Diagnostics Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

GlyCardial Diagnostics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2022510403-A Methods and compositions for the prevention and / or treatment of ischemic injury and ischemic reperfusion injury Pending 05-Dec-2018
EP-3890830-A2 Methods and compositions for the prevention and/or treatment of ischemia and of ischemia/reperfusion injury Inactive 05-Dec-2018
JP-2022506108-A Antibodies specific for glycosylated apoj and their use Pending 23-Oct-2018
AU-2019365391-A1 Antibodies specific for glycosylated apoj and uses thereof Inactive 23-Oct-2018
CA-3115887-A1 Antibodies specific for glycosylated apoj and uses thereof Pending 23-Oct-2018 C07K16/30
To view GlyCardial Diagnostics’s complete patent history, request access »

GlyCardial Diagnostics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GlyCardial Diagnostics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Criteria Bio Ventures Venture Capital Minority
EIT Health Accelerator/Incubator
European Innovation Council Venture Capital Minority
Horizon 2020 Government
Caixa Capital Risc Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

GlyCardial Diagnostics FAQs

  • When was GlyCardial Diagnostics founded?

    GlyCardial Diagnostics was founded in 2017.

  • Where is GlyCardial Diagnostics headquartered?

    GlyCardial Diagnostics is headquartered in Barcelona, Spain.

  • What is the size of GlyCardial Diagnostics?

    GlyCardial Diagnostics has 7 total employees.

  • What industry is GlyCardial Diagnostics in?

    GlyCardial Diagnostics’s primary industry is Drug Discovery.

  • Is GlyCardial Diagnostics a private or public company?

    GlyCardial Diagnostics is a Private company.

  • What is GlyCardial Diagnostics’s current revenue?

    The current revenue for GlyCardial Diagnostics is .

  • How much funding has GlyCardial Diagnostics raised over time?

    GlyCardial Diagnostics has raised $2.91M.

  • Who are GlyCardial Diagnostics’s investors?

    Criteria Bio Ventures, EIT Health, European Innovation Council, Horizon 2020, and Caixa Capital Risc are 5 of 6 investors who have invested in GlyCardial Diagnostics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »